Terms: = Testicular cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
9 results:
1. Leptin promotes proliferation of human undifferentiated spermatogonia by activating the PI3K/AKT/mtor pathway.
Xin S; Xiaoxuan L; Yixuan Z; Zhikang C
Am J Reprod Immunol; 2024 Jan; 91(1):e13811. PubMed ID: 38282611
[TBL] [Abstract] [Full Text] [Related]
2. Effect of rapamycin treatment in human seminoma TCam-2 cells through inhibition of G1-S transition.
Onel T; Erdogan CS; Aru B; Yildirim E; Demirel GY; Yaba A
Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1009-1018. PubMed ID: 36598515
[TBL] [Abstract] [Full Text] [Related]
3. Primary mediastinal seminoma with leiomyosarcoma: a rare case report.
Qi Y; Dong C; Cui W; Da L; Li E; Liu Y; Song F
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):104-108. PubMed ID: 35818265
[TBL] [Abstract] [Full Text] [Related]
4. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German testicular cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract] [Full Text] [Related]
5. [Immunosuppressive therapy and fertility preservation: Indications and methods].
Choux C; Cavalieri M; Barberet J; Samson M; Bonnotte B; Fauque P; Sagot P
Rev Med Interne; 2018 Jul; 39(7):557-565. PubMed ID: 29500075
[TBL] [Abstract] [Full Text] [Related]
6. TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mtor signaling pathway and mitochondria-mediated apoptotic pathway.
Gan Y; Wang Y; Tan Z; Zhou J; Kitazawa R; Jiang X; Tang Y; Yang J
Cancer Biol Ther; 2016 Jul; 17(7):741-50. PubMed ID: 27104982
[TBL] [Abstract] [Full Text] [Related]
7. mtor expression in human testicular seminoma.
Yaba A; Bozkurt ER; Demir N
Andrologia; 2016 Aug; 48(6):702-7. PubMed ID: 26648340
[TBL] [Abstract] [Full Text] [Related]
8. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.
Redig AJ; Munshi HG
Oncology (Williston Park); 2010 Aug; 24(9):839-44. PubMed ID: 20923040
[TBL] [Abstract] [Full Text] [Related]
9. Pediatric genitourinary tumors.
McLean TW; Castellino SM
Curr Opin Oncol; 2008 May; 20(3):315-20. PubMed ID: 18391632
[TBL] [Abstract] [Full Text] [Related]
